Merck and Moderna announced on August 19, 2026, that their personalized mRNA cancer vaccine intismeran autogene, combined with Merck's immunotherapy Keytruda, significantly reduced melanoma recurrence in late-stage trials. Stock prices for both companies surged on the breakthrough.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest." (Source: Bloomberg)
Moderna and Merck said their personalized mRNA cancer treatment, intismeran autogene, met the main goals of a late-stage melanoma trial when combined with Merck’s Keytruda in patients whose high-risk tumors had been surgically removed [nbcboston.com#1][arstechnica.com#1][fortune.com#1][deseret.com#1]. The INTerpath-001 study enrolled 1,137 patients with stage IIB to IV melanoma and reported statis
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
Late state trial met its main goal of showing that the vaccine, combined with another drug, reduced melanoma recurrences more than the immunotherapy alone
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
this outlet adds: awesome, news, hopefully, many, future, looks, little, brighter
A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss. (Source: Bloomberg)
this outlet adds: madison, muller, explains
The vaccine reportedly thwarted the cancer's return and spread.
this outlet adds: arstechnica, health, 2026
this outlet adds: cross, posted, https, slrpnk, post, 41680206
Moderna vaccine cuts recurrence and spread of high-risk melanoma, raising new treatment hope - www.reuters.com/legal/litiga... Moderna said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that ...
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning https://science.slashdot.org/story/26/08/19/1725205/moderna-merck-say-mrna-vaccine-prevents-melanoma-from-returning?utm_source=rss1.0mainlinkanon&utm_medium=feed Moderna and Merck say their personalized mRNA melanoma vaccine significantly reduced both cancer recurrence and spread in a late-stage trial. The treatment could reach patie
edition.cnn.com/2026/08/19/h... A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said Wednesday, potentially opening up a new...
this outlet adds: skeptics, survived, pandemic, hope
this outlet adds: health, treating, disease
this outlet adds: good, news, treating, disease
Moderna shares double on skin cancer vaccine success “custom-made vaccine for each patient depending on their specific tumours. Analysts expect US regulatory approval next year” www.ft.com/content/a98a... Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial
Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
Moderna and Merck said on Wednesday, August 19, that their personalized mRNA therapy intismeran autogene, given with Merck’s immunotherapy Keytruda, met the primary endpoints of the phase 3 INTerpath-001 trial in patients with high-risk melanoma whose tumors had been surgically removed [arstechnica.com#1][okdiario.com#1][mercopress.com#1]. The companies said the combination improved recurrence-fre
American drug companies Merck and Moderna have created a vaccine that has stopped skin cancer returning in patients during a trial. Each vaccine is created specifically for an individual patient by sequencing DNA from patient's tumor and using mRNA to create the vaccine. A new jab extended the length of time patients were cancer free, but it is unclear for how long.
share.newsbreak.com/jcl0b8wt?s=i16 Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
Moderna and Merck said their personalized mRNA cancer therapy intismeran autogene, given with Merck’s Keytruda, met the main goals of a Phase 3 trial in high-risk melanoma patients whose tumors had been surgically removed [fortune.com#1][cnbc.com#1][nbcboston.com#2]. The companies said the combination extended recurrence-free survival and distant metastasis-free survival compared with Keytruda alo
Moderna, the results of the trials for a vaccine against melanoma are surprising https://www.byteseu.com/2291451/ According to what was announced by the company Moderna and its partner Merck, an experimental mRNA vaccine managed to prevent the recurrence or spread of melanoma in a study … According to what was announced by the company Moderna and its partner Merck, an experimental mRNA vaccine man
"The road to new cures can be long and winding. Moderna shows sticking with it can pay off." www.wsj.com/opinion/mode... The company says a trial met its goal to prevent melanoma recurrence.
Moderna announced the first ever positive Phase 3 results for a personalized mRNA cancer vaccine. The vaccine, combined with Merck's Keytruda, showed significant improvement in preventing melanoma recurrence versus Keytruda alone. The treatment works by sequencing each patient's tumor and using AI to identify up to 34 unique cancer markers, then creating a custom mRNA vaccine that trains the immun
Moderna and Merck said their personalized mRNA cancer therapy, intismeran autogene, met the main and secondary goals in a late-stage melanoma trial when combined with Merck’s Keytruda, outperforming Keytruda alone in relapse-free survival and survival without distant metastasis after surgery [pbs.org#1][biznis.rs#1][bursa.ro#1][pharmazeutische-zeitung.de#1]. The companies described the result as t
"Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to target a patient’s unique cancer mutations—was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer. "The announcement was scant on details, but if the success holds, it stands to realize the high aspirations for bot
In terms of medicine, this actually is an exciting time to be alive. A therapy using the same mRNA technology in coronavirus vaccines showed positive results in a trial for skin cancer patients, drugmakers Moderna and Merck said.
🚨"Moderna mRNA Cancer Vaccine Stops Melanoma Returning" Promising trial results suggest cancer vaccines work & could be used to target other tumors. Horrendous # TrumpRegime # InsaneRFK & MAGA/GOP prefer we just die instead https://www. nature.com/articles/d41586-026 -02612-3 # EndCancerNow # VoteOutAllGOP
Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial ->MedicalNewsToday | More on "Melanoma vaccine reduces cancer recurrence" at BigEarthData.ai | #Vaccine #Health Different stages of melanoma have a higher risk of the skin cancer coming back after being surgically removed. An experimental therapy developed by Merck and Moderna aims to help lower the recurrence rate in
Moderna Stock Soars 177 Percent on Melanoma Vaccine Trial, Then Gives Back a Quarter Moderna and Merck announced Wednesday that their personalized mRNA cancer… #CancerVaccine #Merck #Moderna beezloop.com/moderna-stoc... Moderna shares jumped 177 percent after a melanoma vaccine trial succeeded, then fell 24 percent the next day. Here is what the data actually showed and what is still unknown.
Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before